Use of cysteamine and derivatives thereof to suppress tumor metastases

US11844769B2 · kind B2 · utility

Assignees

• MESHABERASE, LLC · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Benjamin Rubin · Jacksonville, US
• Mark J. GILBERT · Seattle, US
• Jinkyu Jung · Bethesda, US

Key dates

• Filing date: Jun 2, 2021
• Grant date: Dec 19, 2023
• Expiry date: Jun 2, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.